Literature DB >> 24619707

TWIST1 expression in breast cancer cells facilitates bone metastasis formation.

Martine Croset1, Delphine Goehrig, Agnieszka Frackowiak, Edith Bonnelye, Stéphane Ansieau, Alain Puisieux, Philippe Clézardin.   

Abstract

The transcription factor TWIST1 induces epithelial-mesenchymal transition and/or escape to the oncogenic-induced failsafe program, facilitating the intravasation of breast cancer cells in the systemic circulation and their dissemination to the lungs. Its involvement in breast cancer bone metastasis is unknown. To address this question, human osteotropic MDA-MB-231/B02 breast cancer cells were stably transfected with a Tet-inducible vector encoding for TWIST1, whose expression was specifically repressed in the presence of doxycycline (dox). The intra-arterial inoculation of transfectants expressing TWIST1 in immunodeficient mice substantially increased the extent of osteolytic lesions in these animals, being 50% larger than that of animals bearing mock-transfected tumors, as determined by radiography. This difference was accompanied by a sharp reduction of the bone volume (indicating a higher bone destruction) and a twofold increase in the tumor volume compared with mice bearing mock-transfected tumors, as determined by histomorphometry. Importantly, the suppression of TWIST1 expression in MDA-MB-231/B02 cells in the presence of dox abolished the stimulatory effect of TWIST1 on bone metastasis formation in vivo. Additionally, examination of the bone marrow from untreated and dox-treated animals on day 7 after tumor cell inoculation, at which time there was no evidence of radiographic osteolytic lesions, revealed that the number of tumor cell colonies that were recovered from the bone marrow of untreated mice was dramatically increased compared with that of dox-fed animals. In vitro, TWIST1 expression promoted tumor cell invasion and enhanced microRNA 10b (miR-10b) expression, a proinvasive factor, but was dispensable for growth of tumor cells. In vivo, the repression of miR-10b substantially decreased the presence of TWIST1-expressing breast cancer cells in the bone marrow. Overall, these results establish that TWIST1 facilitates breast cancer bone metastasis formation through a mechanism dependent of miR-10b, which leads to increase tumor burden and bone destruction.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE; BREAST CANCER; INVASION; METASTASIS; MIR-10B; TWIST1

Mesh:

Substances:

Year:  2014        PMID: 24619707     DOI: 10.1002/jbmr.2215

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

Review 2.  Molecular alterations that drive breast cancer metastasis to bone.

Authors:  Penelope D Ottewell; Liam O'Donnell; Ingunn Holen
Journal:  Bonekey Rep       Date:  2015-03-18

Review 3.  The fundamental role of miR-10b in metastatic cancer.

Authors:  Patrick Sheedy; Zdravka Medarova
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

4.  Protein kinase Cα-mediated phosphorylation of Twist1 at Ser-144 prevents Twist1 ubiquitination and stabilizes it.

Authors:  Roslyn Tedja; Cai M Roberts; Ayesha B Alvero; Carlos Cardenas; Yang Yang-Hartwich; Sydney Spadinger; Mary Pitruzzello; Gang Yin; Carlotta A Glackin; Gil Mor
Journal:  J Biol Chem       Date:  2019-02-07       Impact factor: 5.157

5.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

Review 6.  New therapeutic targets for cancer bone metastasis.

Authors:  Jing Y Krzeszinski; Yihong Wan
Journal:  Trends Pharmacol Sci       Date:  2015-05-09       Impact factor: 14.819

7.  Murine models of breast cancer bone metastasis.

Authors:  Laura E Wright; Penelope D Ottewell; Nadia Rucci; Olivier Peyruchaud; Gabriel M Pagnotti; Antonella Chiechi; Jeroen T Buijs; Julie A Sterling
Journal:  Bonekey Rep       Date:  2016-05-11

8.  VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.

Authors:  Haihong Pu; Qingyuan Zhang; Chunbo Zhao; Lei Shi; Yan Wang; Jingxuan Wang; Minghui Zhang
Journal:  Pathol Oncol Res       Date:  2017-07-25       Impact factor: 3.201

Review 9.  Tumour-derived miRNAs and bone metastasis.

Authors:  Martine Croset; Casina Kan; Philippe Clézardin
Journal:  Bonekey Rep       Date:  2015-05-13

Review 10.  MicroRNA Exert Macro Effects on Cancer Bone Metastasis.

Authors:  Scott R Baier; Yihong Wan
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.